Make a big difference for Parkinson’s research
This Spring, we're funding the biggest ever Parkinson's clinical trial. Your support can fund the next big breakthrough, and help find better treatments sooner.
Fund the next big breakthrough
£10 could fund 40 collection tubes to store vital samples that could provide researchers in
the EJS ACT-PD clinical trial with the data needed to unlock new treatments.
- Paypal accepted
- Mastercard accepted
- Visa accepted
- American Express accepted
By 2050, the number of people living with Parkinson’s worldwide will double to 25 million
It can take decades for traditional treatments to reach people living with Parkinson’s. We urgently need to improve the speed and efficiency of trials.
Your support today ensures that we keep testing, learning, and working until we find the treatments that will stop Parkinson's. Together we can give people living with Parkinson’s a reason to believe in a brighter future.
Why the EJS ACT-PD trial is groundbreaking:
The Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease (EJS ACT-PD) trial is the largest Parkinson’s clinical trial ever carried out in the UK, bringing together researchers to drive progress faster than ever before.
With 1,600 people with Parkinson’s across 40 hubs in the UK, this new style of trial changes everything:
-
Multi-Arm, Multi-Stage (MAMS): For the first time in Parkinson’s research, multiple treatments can be tested at the exact same time, giving us more answers quickly and efficiently.
-
We can check early on to see if treatments appear to be working. If they aren’t, they are removed, and new ones are added.
-
The trial focuses on repurposed drugs—medications already proven safe for other conditions. They are already in Phase 3 of clinical testing, the final hurdle before approval.
-
This approach has been highly effective for other conditions including Multiple Sclerosis and prostate cancer. For example, the STAMPEDE clinical trial used this method to find new combinations of treatments that improved the overall survival rate for high-risk prostate cancer. Now, we’re using it for Parkinson’s.
Led by experts, driven by people with Parkinson's
With over 90 scientists from across the world coming together to establish EJS ACT-PD, we hope to find better treatments, faster.
Professor Tom Foltynie (UCL): “When looking for new treatments for Parkinson’s, what frustrates everyone is the length of time it takes just to assess 1 treatment... Tested one at a time, with each drug going through different clinical phases.” The EJS ACT-PD trial is set to change that.
Professor Camille Carroll (Newcastle University) is also leading alongside Professor Foltynie as part of a powerful global movement of scientists and innovators.
The trial continues to focus on meeting the needs of people with Parkinson’s and their loved ones.
Make a big difference today
To be part of the world’s biggest trials like EJS ACT-PD, we count on people like you. Please make a donation to fund more research. Together, we find better treatments and a cure, sooner.
The Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease (EJS ACT-PD) trial is the largest Parkinson’s clinical trial ever carried out in the UK, bringing together researchers and people with parkinson's to drive progress faster than ever before.
Our Research Support Network (RSN) brings together people driven to help find a cure and better treatments for Parkinson’s. Whether you have Parkinson's or not, there are many ways to get involved.
Find out how you can get involved in research and help us power breakthroughs.